His main research concerns MAPK/ERK pathway, Signal transduction, Cell biology, Cancer research and PI3K/AKT/mTOR pathway. His research in MAPK/ERK pathway is mostly concerned with Anti-apoptotic Ras signalling cascade. Specifically, his work in Signal transduction is concerned with the study of Mitogen-activated protein kinase.
His Cell biology research integrates issues from Cell cycle and Receptor, Biochemistry. Richard A. Franklin frequently studies issues relating to Protein kinase B and PI3K/AKT/mTOR pathway. His work carried out in the field of PTEN brings together such families of science as Carcinogenesis, Protein phosphatase 2 and Targeted therapy.
Richard A. Franklin mainly investigates Cell biology, Cancer research, Signal transduction, MAPK/ERK pathway and Protein kinase B. The various areas that Richard A. Franklin examines in his Cell biology study include Cell cycle, Jurkat cells and Cell growth. Richard A. Franklin works mostly in the field of Cancer research, limiting it down to topics relating to Cancer and, in certain cases, Oncology, as a part of the same area of interest.
His Signal transduction study integrates concerns from other disciplines, such as Apoptosis, Cell culture and Cytokine. His MAPK/ERK pathway research incorporates themes from Receptor, Stimulation and Mitogen-activated protein kinase kinase. Richard A. Franklin interconnects Carcinogenesis, PI3K/AKT/mTOR pathway and Epidermal growth factor receptor in the investigation of issues within Protein kinase B.
Cancer research, PI3K/AKT/mTOR pathway, Protein kinase B, MAPK/ERK pathway and PTEN are his primary areas of study. His biological study spans a wide range of topics, including Apoptosis and Cancer, Targeted therapy, Treatment resistance. His PI3K/AKT/mTOR pathway study combines topics from a wide range of disciplines, such as Tamoxifen and Breast cancer.
His studies deal with areas such as Mediator and Tetrandrine as well as Protein kinase B. Part of his project on MAPK/ERK pathway includes research on Cell biology and Signal transduction. His PTEN research is multidisciplinary, incorporating elements of Carcinogenesis and Protein phosphatase 2.
His primary areas of study are Protein kinase B, PI3K/AKT/mTOR pathway, PTEN, Cancer research and MAPK/ERK pathway. His Protein kinase B study is related to the wider topic of Cell biology. The study incorporates disciplines such as Tumor suppressor gene and Treatment resistance in addition to PI3K/AKT/mTOR pathway.
His Tumor suppressor gene study combines topics from a wide range of disciplines, such as Phosphatase and Tensin. Cell growth is closely connected to Cell cycle in his research, which is encompassed under the umbrella topic of PTEN. Kinase, Anti-apoptotic Ras signalling cascade and c-Raf are fields of study that intersect with his HRAS research.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
ROLES OF THE RAF/MEK/ERK PATHWAY IN CELL GROWTH, MALIGNANT TRANSFORMATION AND DRUG RESISTANCE
James A. McCubrey;Linda S. Steelman;William H. Chappell;Stephen L. Abrams.
Biochimica et Biophysica Acta (2007)
Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy
F Chang;J T Lee;P M Navolanic;L S Steelman.
Reactive oxygen species-induced activation of the MAP kinase signaling pathways.
James A. McCubrey;Michelle M. LaHair;Richard A. Franklin.
Antioxidants & Redox Signaling (2006)
Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention
F Chang;L S Steelman;J T Lee;J G Shelton.
JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis.
L S Steelman;S C Pohnert;J G Shelton;Richard A Franklin.
Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
James A. McCubrey;Linda S. Steelman;Steven L. Abrams;John T. Lee.
Advances in Enzyme Regulation (2006)
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health
William H. Chappell;Linda S. Steelman;Jacquelyn M. Long;Ruth C. Kempf.
Regulation of cell cycle progression and apoptosis by the Ras/Raf/MEK/ERK pathway (Review)
Fumin Chang;Linda S. Steelman;John G. Shelton;John T. Lee.
International Journal of Oncology (2003)
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance
James Andrew McCubrey;Linda S. Steelman;William H. Chappell;Stephen L. Abrams.
Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy.
L S Steelman;R A Franklin;S L Abrams;W Chappell.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: